CDSCO : In November, the Central Drugs Standard Control Organisation (CDSCO) determined that 111 drug samples were ‘not of standard quality’. Out of 111 drugs, 41 were tested in a central laboratory and 70 in state labs.
It should be emphasized that the identification of medication samples as NSQ is based on their failure to meet one or more of the stated quality requirements. “The failure is specific to the drug products of the batch tested by the government laboratory and it does not warrant any concerns on the other drug products available in the market,” according to an official.
Table of Contents
CDSCO collects and analyzes medication samples
As part of ongoing regulatory oversight, the CDSCO collects and analyzes medication samples from sales/distribution locations. As a result, a list of Not of Standard Quality (NSQ) medications is published on the CDSCO web each month. The current list of NSQ medicines was compiled from samples tested in November.
According to the CDSCO, the goal of displaying the NSQ list is to inform stakeholders about the NSQ batches that have been discovered in the market. Notably, the list includes the drug’s content, date of manufacture, and expiry date, as well as the manufacturer’s name and the test it failed.
List of NSQs tested in the Center laboratory
Two medicines found spurious
Meanwhile, two medicine samples were discovered as bogus in November. The Bihar Drugs Control Authority selected one of the two samples, while CDSCO, Ghaziabad selected the other, according to sources. The medications were produced by unapproved and unknown manufacturers who used other corporations’ brand names.
These medications include Pantoprazole Gastro-Resistant Tablets I.P. (PAN-40) with batch number 23443074 and Amoxycillin and Potassium Clavulanate Tablets IP (AUGMENTIN625 DUO) with batch number 824D054.
you join our tazatimesnews Telegram Channel
you join our whatsapp channel
Next News Read – Sachin Tendulkar accepts MCC’s Honorary Cricket Membership
